

Protein C concentrate (human)
(Ceprotrin®)

Place of Service
Office Administration
Home Infusion Administration
Outpatient Facility Administration
Infusion Center Administration

HCPCS: J2724 per 10 IU

Conditions listed in policy (see criteria for details)

- [Prevention and treatment of venous thrombosis and purpura fulminans in patients with severe congenital Protein C deficiency](#)

AHFS therapeutic class: Anticoagulant

Mechanism of action: Protein C inactivates the activated forms of factors V and VIII with subsequent reduction thrombin formation

(1) Special Instructions and Pertinent Information

Covered under the Medical Benefit, please submit clinical information for prior authorization review.

(2) Prior Authorization/Medical Review is required for the following condition(s)

All requests for Ceprotrin® (protein C concentrate) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

Congenital Protein C deficiency, prevention and treatment of associated venous thrombosis and purpura fulminans

Covered Doses

Up to 3,000 units given by IV per date of service

Coverage Period

Indefinite

ICD-10:

D68.59

(3) The following condition(s) DO NOT require Prior Authorization/Preservice

All requests for Ceprotrin® (protein C concentrate) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

(4) This Medication is NOT medically necessary for the following condition(s):

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

(5) Additional Information

How supplied:

Single-dose vials that contain the following nominal product strengths

PHP Medi-Cal

Protein C concentrate (Ceprotrin®)

- 500 IU per vial
- 1000 IU per vial

(6) References

- AHFS®. Available by subscription at <http://www.lexi.com>
- Ceprotin (Protein C Concentrate (Human)) [Prescribing Information]. Lexington, MA. Baxalta Inc. 3/2023.
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>

(7) Policy Update

Date of initial review: 1Q2024

Date of next review: 1Q2025

Changes from previous policy version:

- No clinical change to policy following routine annual review.

*BSC Drug Coverage Criteria to Determine Medical Necessity
Reviewed by P&T Committee*